Germline and somatic POT1 mutations and the dysregulation of POT1 expression have been detected across different cancer types, most prevalently in cutaneous melanoma and squamous cell carcinoma, angiosarcoma, non-small-cell carcinoma of the lung and chronic lymphocytic leukemia (CLL). This evidence concerns the gene POT1 and B-cell chronic lymphocytic leukemia.